Home › Research › How common it is
Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK et al.. JAMA internal medicine, 2015-03-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Importance Many medications have anticholinergic effects. In general, anticholinergic-induced cognitive impairment is considered reversible on discontinuation of anticholinergic therapy. However, a few studies suggest that anticholinergics may be associated with an increased risk for dementia. Objective To examine whether cumulative anticholinergic use is associated with a higher risk for incident dementia. Design, setting, and participants Prospective population-based cohort study using data from the Adult Changes in Thought study in Group Health, an integrated health care delivery system in Seattle, Washington. We included 3434 participants 65 years or older with no dementia at study entry. Initial recruitment occurred from 1994 through 1996 and from 2000 through 2003. Beginning in 2004, continuous replacement for deaths occurred. All participants were followed up every 2 years. Data through September 30, 2012, were included in these analyses. Exposures Computerized pharmacy dispensing data were used to ascertain cumulative anticholinergic exposure, which was defined as the total standardized daily doses (TSDDs) dispensed in the past 10 years. The most recent 12 months of use was excluded to avoid use related to prodromal symptoms. Cumulative exposure was updated as participants were followed up over time. Main outcomes and measures Incident dementia and Alzheimer disease using standard diagnostic criteria. Statistical analysis used Cox proportional hazards regression models adjusted for demographic characteristics, health behaviors, and health status, including comorbidities. Results The most common anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and bladder antimuscarinics. During a mean follow-up of 7.3 years, 797 participants (23.2%) developed dementia (637 of these [79.9%] developed Alzheimer disease). A 10-year cumulative dose-response relationship was observed for dementia and Alzheimer disease (test for trend, P Conclusions and relevance Higher cumulative anticholinergic use is associated with an increased risk for dementia. Efforts to increase awareness among health care professionals and older adults about this potential medication-related risk are important to minimize anticholinergic use over time.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 3,434 participants. In 3,434 adults aged 65+ in Seattle followed for a mean of 7.3 years, those who had filled more anticholinergic prescriptions over the previous 10 years were more likely to develop dementia and Alzheimer's, with risk rising as cumulative dose rose. Reported effect size: 23.2%; 79.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., et al. (2015). Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA internal medicine. https://doi.org/10.1001/jamainternmed.2014.7663
Vancouver
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA internal medicine. 2015. doi:10.1001/jamainternmed.2014.7663. PMID: 25621434.
BibTeX
@article{gray2015-25621434,
author = {Gray, S. L. and Anderson, M. L. and Dublin, S. and Hanlon, J. T. and Hubbard, R. and Walker, R. and Yu, O. and Crane, P. K. and others},
title = {{Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study}},
journal = {JAMA internal medicine},
year = {2015},
doi = {10.1001/jamainternmed.2014.7663},
pmid = {25621434},
url = {https://doi.org/10.1001/jamainternmed.2014.7663}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, a few studies suggest that anticholinergics may be associated with an increased risk for dementia.
- Objective To examine whether cumulative anticholinergic use is associated with a higher risk for incident dementia.
- Results The most common anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and bladder antimuscarinics.
- A 10-year cumulative dose-response relationship was observed for dementia and Alzheimer disease (test for trend, P Conclusions and relevance Higher cumulative anticholinergic use is associated with an increased risk for dementia.
Why it matters
In 3,434 adults aged 65+ in Seattle followed for a mean of 7.3 years, those who had filled more anticholinergic prescriptions over the previous 10 years were more likely to develop dementia and Alzheimer's, with risk rising as cumulative dose rose. The drugs most used were tricyclic antidepressants, first-generation antihistamines and bladder antimuscarinics. This is an association, not proof the drugs cause dementia or that stopping them prevents it. The authors call for more awareness among clinicians and older adults so these drugs are used less over time.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designcohort study
- Participants3,434
- Effect size23.2%; 79.9%
- Evidence strengthModerate
How this study scored 77/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA internal medicine) |
| Journal's citation record | 3 / 4 | JAMA Internal Medicine: journal h-index 258 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,434 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,105 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 85.0 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 6 / 6 | Cited 44.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 15 other studies in this library |
| Still being cited | 4 / 4 | Cited 275 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Eric B. Larson: h-index 105 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25621434) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 77 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamainternmed.2014.7663
- PubMed: 25621434
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in How common it is from nearby years
Also tagged “sedative-antipsychotic-harm-in-dementia”
4 studies in the library carry the topic tag “sedative-antipsychotic-harm-in-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.